Poland· PL-100230814
Stelara
A ustekinumab product containing ustekinumabum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ustekinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC05 (ustekinumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Ustekinumab · ATC L04AC05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ustekinumab costs, country by country.
Normalised to the WHO defined daily dose (0.54 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ustekinumab · price per daily dose (0.54 mg)
USD · FX 28 Sept 2026
- CH Switzerland$7.71
The record
At a glance
URPL (Poland)- Active substance
- Ustekinumabum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L04AC05
- ATC class
- Ustekinumab
- Defined daily dose
- 0.54 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909997077512
- gtin05413868122589
- gtin04150184954104
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
399 interactions on record for ustekinumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ustekinumab · interactions on record
399 records
- 30 severe
- 362 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ustekinumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAbsimky 90 mgAccord Healthcare
- United KingdomImuldosa 45mg/0.5ml solution for injection pre-filled syringesAccord-UK Ltd
- CzechiaFYMSKINAFormycon AG, Martinsried/Planegg
- SwedenFymskina 90 mg Injektionsvätska, lösning i förfylld sprutaFormycon AG
- SpainABSIMKY 90 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAccord Healthcare S.L.U.
- IcelandFymskinaFormycon AG
- NorwayPyzchivaSamsung Bioepis NL B.V.
- DenmarkABSIMKYAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Imuldosa, Uzpruvo
- Iceland · Fymskina, Imuldosa
- Liechtenstein · Fymskina, Imuldosa
- Norway · Fymskina, Imuldosa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f62d4091-b21b-4a77-bca4-d98f17199e16 GET /v1/drugs/f62d4091-b21b-4a77-bca4-d98f17199e16?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "90 mg",
"packaging": "05909997077512 ¦ Rpz ¦ EU/1/08/494/004 ¦ 59668\n1 amp.-strzyk. 1 ml\n05413868122589 ¦ Rpz ¦ EU/1/08/494/007 ¦ 151218\n1 wstrzykiwacz 1 ml\n¦ UR/Z/4c/119/23 - 04150184954104",
"substance": "Ustekinumabum 90 mg",
"common_name": "Ustekinumabum",
"pl_product_id": "100230814",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ustekinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.